Back to Search
Start Over
Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers
- Source :
- Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 33(5)
- Publication Year :
- 2013
-
Abstract
- The combined use of batifiban, a synthetic platelet GPII b/ IIIa receptor antagonist, and antithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS) and those scheduled for percutaneous coronary intervention. To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted. Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents. Blood samples were collected at pre-specified time points. The evaluation index included the inhibition of platelet aggregation and pharmacokinetic parameters. The pharmacokinetic parameters of batifiban and batifiban coadministered with antithrombin agents showed no significant differences. The mean inhibition rate of platelet aggregation (%) suggested that neither batifiban alone nor antithrombin agents alone could provide such potent inhibition rate (>80%) to obtain the best clinical efficacy, but they had a synergistic effect on platelet inhibition. No serious adverse effects were observed. The results in these healthy subjects suggest that batifiban coadministrated with antithrombin agents could achieve optimum clinical treatment effect for patients with NSTE ACS, and also those scheduled for percutaneous coronary intervention.
- Subjects :
- Adult
Male
Acute coronary syndrome
China
Ticlopidine
Time Factors
Adolescent
Metabolic Clearance Rate
medicine.medical_treatment
Biomedical Engineering
Administration, Oral
Pharmacology
Biochemistry
Peptides, Cyclic
Drug Administration Schedule
Biomaterials
Young Adult
Fibrinolytic Agents
Genetics
medicine
Humans
Adverse effect
Infusions, Intravenous
Earth-Surface Processes
Aspirin
business.industry
Heparin
Antithrombin
Percutaneous coronary intervention
medicine.disease
Clopidogrel
Pharmacodynamics
Glycoprotein IIb/IIIa inhibitors
Area Under Curve
Injections, Intravenous
Female
business
Platelet Aggregation Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 16720733
- Volume :
- 33
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
- Accession number :
- edsair.doi.dedup.....cde0ff0dca95a8a52a80e3eee09a7db9